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 ABSTRACT 
Introduction 
 Myocardial infarction is the most cause of heart failure. The incidence of heart failure 
after MI has been reported as high as 23% in various studies. Characteristics of patients in India 
who develop heart failure after a myocardial infarction are less well studied. Though presence of 
higher incidence of reduced LV function with delay in revascularization time is established, rates 
of reduced LV function after different modes of revascularization and correlation with coronary 
artery lesion is not well established. 
Aim and Objectives 
 To study the incidence of left ventricular dysfunction after the initial episode of 
myocardial infarction and to determine the difference in rates of development of LV dysfunction 
depending on time to perform revascularization and based on mode of revascularization and to 
correlate the development of LV dysfunction with the coronary artery lesion as determined by 
coronary angiogram. 
Methodology 
 93 patients admitted in PSG Hospital from 1
st
 March 2013 to 31
st
 December 2013 with a 
diagnosis of Acute ST Elevation Myocardial Infarction and undergoing reperfusion therapy with 
either streptokinase or by percutaneous coronary intervention were included. Window period and 
door to needle/door to balloon time are recorded. Left ventricular ejection fraction, as determined 
by volumetric method, is measured within first 24 hours and on day 5 by a single person to avoid 
interpersonal variation. Development of heart failure based on Framingham criteria is noted. Use 
of diuretics is noted. Coronary artery lesion by coronary angiogram is noted. 
 Results 
 Out of 93 patients included in the study, 32 underwent primary PCI and 61 underwent 
thrombolysis. Patients with longer reperfusion time showed a significant reduction in LV 
ejection fraction. Patients retaining a normal ejection fraction when reperfusion times are 
between 0-3, 3-6, 6-12 and more than 12 were 70%, 59%, 32% and 0 respectively. Patients who 
underwent primary PCI had more chance of a preserved LVEF compared to those who 
underwent thrombolysis (82% Vs 44%. p=0.013). Patients with anterior wall STEMI had less 
number of patients with normal LVEF when reperfusion times were between 3 to 6 hours (41% 
Vs 93%. p=0.001) compared to non-anterior wall STEMI patients. No significant associations 
were found between age, presence of diabetes and the number of vessels involved to LVEF. 
Conclusion 
 Longer reperfusion times are associated with significant reduction in LVEF. Primary PCI 
leads to better outcome in patients presenting between 3-6 hours when compared with 
thrombolysis. AW STEMI patients develop significant reduction in LVEF at 3-6 hours compared 
to non-AW STEMI patients.  
  
 INTRODUCTION 
Coronary artery disease (CAD) is a major cause of death and disability in developed and 
developing countries. As of 2012, CAD is the most common cause of death in the world 
[1]
 and 
also the major cause of hospital admissions 
[2]
. Though high-income countries are seeing a fall in 
the incidence of CAD, low- and middle-income countries are seeing a very alarming increase in 
the rates of CAD, and this change is accelerating. In 2001, 75% of all global deaths and 82% of 
total DALYs (Disability Adjusted Life Years) lost due coronary artery disease occurred in low- 
and middle-income countries 
[3]
.  
Mortality from coronary artery disease is expected to increase in developing countries 
(including India, China, Middle East, sub-Saharan Africa and Latin America), from an estimated 
9 million in the year 1990 to a projected 19 million by the year 2020 
[4]
. It is thought that this 
projected increase is a consequence of social and economic changes in non-Western countries, 
which has led to an increased life expectancy, physical inactivity, changing/westernized diets, 
and an increase in cigarette smoking in these countries 
[5]
. 
Coronary artery disease affects people at a much younger age in low- and middle-income 
countries compared to high-income countries. This leads to a greater economic impact on low- 
and middle-income countries. Effective screening, evaluation, and management strategies for 
coronary artery disease are well established in developed countries, but these strategies have not 
been fully implemented in developing countries like India. 
Heart failure is the most common complication of coronary artery disease including ST 
elevation myocardial infarction (STEMI). Coronary artery disease accounts for 50% to 70% of 
incident cases of heart failure. Coronary heart disease has a relative risk of 8.1 for producing 
 heart failure. Overall Population Attributable Risk was 62 percent with 68 percent in men and 56 
percent in women.  
The increasing prevalence of heart failure in the world is in part due to the improved 
survival after myocardial infarction, successful prevention of sudden cardiac deaths and the 
ageing population. In the Framingham Heart Study, the prevalence of HF in men was 8 per 1000 
at age 50 to 59 years and increased to 66 per 1000 at ages 80 to 89 years. There are an estimated 
23 million people with HF worldwide 
[9]
. Heart failure is a major cause of sick leaves, early 
retirement, hospitalizations and rising health care costs throughout the world.  
Despite improvements in therapy of heart failure, the mortality and morbidity rates in 
patients with HF has remained unacceptably high. Continued efforts are therefore necessary to 
reduce the incidence of HF. One of the most important variables involved in the incidence of 
heart failure after a myocardial infarction is the time to reperfusion. Reducing the time to 
reperfusion, which is assessed by door-to-balloon or door-to-needle time and symptom-to-
balloon or symptom-to-needle time is therefore crucial in improving myocardial salvage and 
preventing heart failure. 
Door-to-balloon or door-to-needle time is mostly determined by organizational factors    
including presentation within regular working hours, rapid diagnosis, activation of 
catheterization laboratory both during working hours and non-working hours. Symptom-to-
balloon or symptom-to-needle time is mainly dependent on patient factors. Current 2013 ACC 
guidelines give a value of 30 minutes for door-to-needle time and 90 minutes for door-to-balloon 
time with the aim of reducing the total ischemia time to less than 120 minutes. 
 However, the times given in guidelines are most often impossible to achieve in the 
current Indian hospital setting due to many factors including poor awareness among the 
population about the symptoms of myocardial infarction, lack of rapid transportation/ambulance 
facilities, shortage of trained staff in hospitals and lack of catheterization laboratories except in 
tertiary care centers.   
Reduction in the time to reperfusion has not only shown to reduce the mortality due to 
myocardial infarction but several studies have also shown that it can reduce the incidence of 
heart failure after myocardial infarction. The difference in incidence of heart failure among 
patients who undergo percutaneous intervention and those who undergo thrombolysis is less well 
established. Also, the relationship of other variables like age, sex and presence of risk factors and 
their association with the incidence of reduced LVEF and heart failure after myocardial 
infarction in the Indian setting have not been well documented.  
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES 
 
 To determine the incidence of reduced left ventricular ejection fraction after acute 
STEMI in patients undergoing reperfusion. 
 To analyze the characteristics of patients developing reduced left ventricular ejection 
fraction and heart failure with respect to time from onset of symptoms to start of therapy, 
presence of risk factors and number of coronary vessels involved. 
 To analyze if there is any difference in incidence of reduced left ventricular function 
between patients who undergo thrombolysis versus those who undergo primary PCI. 
 
 
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE 
History of Coronary Artery Disease 
Death from coronary artery disease was relatively rare before 1900. The industrial 
revolution and the present day modern comfort are believed to have contributed significantly to 
the rise of coronary artery disease. Leonardo da Vinci is among the earliest scientists 
documented to have studied coronary arteries and their purpose. In 1628, an English doctor, 
William Harvey, described the circulation of blood. In the 1700s, cardiologist Friedrich 
Hoffmann established the link between coronary artery disease and decreased blood flow 
through the coronary arteries.  
In 1768, William Heberden, an English physician, published his observations about the 
relationship of ischemic heart disease and coronary vascular anatomy. Since then, up to 19
th
 
century the disease was called the „Heberden‟s disease‟. In 1879, Ludwig Hekben, by his studies 
concluded that myocardial infarction was due to coronary obstruction which was secondary to 
thrombosis. William Osler played a large role studying angina and giving an accurate description 
of the coronary vessels. James Herrick is credited with coining the phrase "heart attack." 
According to Cournand, the first catheterization was done by Claude Bernard in 1844 in a 
horse. In 1929, Werner Forssmann conducted the first coronary heart catheterization on himself. 
Forssmann, a urologist, while working on his experiments introduced a catheter into his jugular 
vein and took an X-ray and found it to be inside the right atrium. This groundbreaking work 
sparked other advances in this field and by the 1950s physicians were developing angiography, 
which is a process of making blood vessels viewable by X-ray. 
 In 1941, André Cournand and Dickinson Richards successfully repeated the trial of 
Forssmann. With their repeated attempts and experiments, they were finally able to push the 
catheter into right ventricle and take right ventricular angiograms. In 1950‟s the forthcoming 
experiments by them were a milestone in history towards the present day cardiac interventions. 
Coronary arteriography and ventriculography became the gold standard for studying the 
cardiac and vessel anatomy and left ventricular pump function. They gave valuable information 
which made the way for surgical treatment for coronary revascularizations. Dotter, Judkins and 
Andreas Gruntzig conducted many experiments which led to the advances in invasive 
cardiology. 
The first coronary bypass surgery was done in Cleveland Clinic in 1967. Dr. Rene 
Favaloro was the pioneer of the open-heart techniques, which involved the removal of a vein 
from one part of a patient‟s body and using it to connect the aorta and coronary arteries, creating 
a "bypass" around blocked coronary arteries. Dr. Andreas Gruentzig performed the first coronary 
angioplasty in 1977 in Switzerland. Dr. Gruentzig inserted a catheter into a coronary artery that 
was blocked and inflated a tiny balloon made at his kitchen table and compressed the buildup of 
plaque against the walls of the artery according to The Society for Cardiovascular Angiography 
and Interventions. 
1986 saw the development of tiny metal stents that serve to prop open the artery and keep 
it from closing again after balloon angioplasty. Need for invasive, higher-risk surgeries was 
reduced due to the usage of stents which became commonplace. By 2002, more than 2 million 
coronary angioplasties were performed annually across the globe and drug eluting stents were 
developed. 
 Definition of Myocardial Infarction 
The definition of myocardial infarction is given by ESC/ACCF/AHA/WHF Task Force 
for the Universal Definition of Myocardial Infarction. 
 
 Classification of Myocardial Infarction 
This is also given by ESC/ACCF/AHA/WHF Task Force for the Universal Definition of 
Myocardial Infarction. 
 
Epidemiology 
Global Trends in Cardiovascular Disease 
85% of the world‟s population lives in low and middle-income countries.  Cerebro 
vascular disease (CVD) incidence rates in these countries largely accounts for global rates of 
CVD. Though CVD rates are falling in high-income countries, CVD rates worldwide are 
increasing because most low and middle-income countries are entering the second and third 
 phases of the epidemiologic transition, featured by rising CVD rates. CVD will be the dominant 
factor in economic impact of chronic diseases. Countries such as China, India, and Russia would 
be spending between $200 and $550 billion in national income as a result of heart disease, 
stroke, and diabetes 
[9]
. 
In 1990, CVD accounted for 28% of the 50.4 million deaths worldwide and 9.8% of the 
1.4 billion lost DALYs. By 2030, WHO predicts that worldwide, CVD will be responsible for 
nearly 24 million deaths. Of these CAD will cause 14.9% deaths in men and 13.1% deaths in 
women and stroke will be the cause of 10.4% of deaths in men and 11.8% of deaths in women. 
Prevalence of CAD in India 
In India, coronary artery disease rates have increased during the last 30 years in contrast 
to declining trends that have been noticed in developed Western countries. The high prevalence 
of CAD in Indians came to light after the detection of increased incidence of CAD and MI in 
Indians living abroad. More than 20 million Indians live abroad and nearly 1.7 million of them in 
the USA. The Kaiser study 
[10]
 showed a prevalence of CAD in Indians in the US to be nearly 3 
to 4 times than that of the American population, 6 times higher than Chinese population 
[17]
 and 
20 times higher than the Japanese 
[16]
. Indians develop heart disease 10 years earlier than other 
populations. 
The prevalence of CAD in North India has increased from 1% in 1960 to 10.5% in 
1998
[12]
 and that in south India is 11% to 14.3% 
[13]
, slightly more than in north India and in 
Indians in the US. A study from Calicut Medical College in Kerala 
[15]
 showed that first heart 
attacks in patients aged less than 40 have increased 20-times between 1971 and 1991. 
 According to the WHO, in 1990 nearly 1.2 million died from heart disease and by 2020, 
100 million Indians will have CAD (nearly 25% of world‟s CAD patients). Hence India is set to 
become the „CAD capital of the world‟ as well, in addition to Diabetes and sooner still the 
Hypertension capital of the world as 1 in 5 people in Chennai have been found to be 
hypertensive. 
CAD occurs equally in both vegetarians and non-vegetarians. The prevalence of CAD in 
urban population is twice that in rural population though smoking is more prevalent in the rural 
areas and in the face of the fact that CAD has doubled in rural areas as well 
[14]
. 
 
 
 
 Special Features of CAD in Indians 
 Many studies came upon some salient features of coronary artery disease epidemic 
among Indians 
[15] [18] [19] [20] 
 India led the world with 1,531,534 cardiovascular disease related deaths in 2002  
 Median age of first heart attack is 53 years in Indians compared to 63 in other groups  
 Incidence of CAD in young Indians is about 12%–16%, which is the highest among any 
other ethnic group 
 About 5%–10% of heart attacks occur in Indian men and women younger than 40 years 
 Left main and triple vessel disease is twice as common than in whites not only in males 
but also in females 
 Pre-hospital cardiac arrest is more common than in other ethnic groups. 
Risk Factors for CAD in Indians 
Indians have a higher prevalence of CAD in presence of low cardiac risk factors like 
obesity, smoking, cholesterol and hypertension as was seen in the CADI study. This feature has 
been called the Indian paradox.  Other factors like DM, physical inactivity, low HDL levels are 
more prevalent in Indians. A number of other risk factors like lipoprotein (a), metabolic 
syndrome, homocysteine, fibrinogen, C-reactive protein (CRP) are also more common in the 
Indians 
[28]
. 
If any three of the conventional risk factors are present the risk of CAD increases 13 fold, 
but the addition of increased lipoprotein (a) levels increases the risk 43-fold 
[25]
. Lipoprotein(a) is 
 genetically inherited and makes Indians more susceptible to heart disease at a young age. It 
amplifies the effect of high LDL and low HDL cholesterol, and hastens atherosclerosis.  
High homocysteine levels occur with improper diet and cooking methods. High levels of 
CRP are associated with abdominal obesity and sedentary life. Diabetes is 2-4 times more 
common among Indians than other ethnic groups 
[24]
. Incidence of diabetes mellitus has doubled 
in the rural population and tripled in urban population over the past three decades. Indians 
develop diabetes mellitus earlier (10- 15 years) and at a lower body weight (9.1 to 13.6 kg) than 
other ethnic groups. 
Between 2000 and 2030, diabetic population in India is projected to go up from 32 
million to 79 million. Diabetes mellitus and CAD are inextricably intertwined 
[24]
; one causes the 
other within 10 to 20 yrs. The incidence of CAD among diabetics is 14-times higher in those 
below 45 years and 2-3 times more in those older. 
Use of stricter Asia Pacific Criteria for abdominal obesity resulted in a 50% increase in 
prevalence of metabolic syndrome from 22% to 32% in Indian men and from 20% to 29% in 
Indian women in Singapore 
[23]
. Metabolic syndrome is typically associated with atherogenic 
phenotype B characterized by hypertriglyceridemia, low HDL-C, high small dense LDL, high 
apolipoprotein B and low apolipoprotein A-1. This explains the very high risk of CAD in 
metabolic syndrome. 
About 20% of diabetics do not have metabolic syndrome and have a greatly reduced risk 
of CAD. Conversely, people with metabolic syndrome have a substantially increased risk of 
CAD even in absence of diabetes 
[22]
. 
 CURES study by Mohan et al 
[21]
 clearly shows every fifth individual is hypertensive in 
Chennai which is equal to or greater than the incidence of diabetes.  Prevalence of hypertension 
in the study population was 20%, (23.2% in men and 17.1% in women).  Even in the young (20-
29 years), the incidence of hypertension was 3.8% in men and 3.1% in women. At the age of >60 
years the incidence was 50.8% in men and 51% in women. The number of people with 
hypertension may overtake diabetics in our subcontinent. 
INTERHEART study 
[20]
 was done by Yusuf et al in 2004 showed that the risk factors 
among Indians to be slightly different from other ethnic groups. It showed hypertension (OR 
2.89), diabetes (OR 2.48) and abdominal obesity (OR 2.43) had more severe effects in South 
Asia, whereas psychosocial factors had a lesser OR of 2.15, compared with 2.67 worldwide. It 
also showed hypertension and diabetes were more important risk factors in younger women than 
men in India. Factors peculiar to the South Asian population such as truncal obesity, high TGL 
and low HDL-C were also found.  
North Indians manifest coronary artery disease at lower levels of total cholesterol than 
South Indians. Lower HDL-C and higher TGL levels in both younger and older coronary artery 
disease patients appear to be a hallmark of the Indian population. There was also a greater 
association of smoking with CAD in younger individuals especially young men than young 
women. Prevalence of smoking in South Indian males (44.6%) and the prevalence of passive 
smoking in South Indian females (45.3%) has been found out to be significantly higher than in 
North Indians. 
 Process of Atherosclerosis 
Atherosclerosis is a process that starts soon after birth as soon as the infant starts feeding 
diet that contains fat. Low-density lipoprotein (LDL) particles begin adhering to the vessel wall 
and accumulating in the intima. These get oxidized and become oxidized LDL. These oxidized 
lipoprotein particles releases cytokines which attracts the monocytes. The next process starts 
with the adherence of circulating blood monocytes to the endothelium. This is favored by the 
expression of molecules like vascular cell adhesion molecule 1 (VCAM-1), intercellular 
adhesion molecule 1 (ICAM-1) and selectins (includes both E-Selectin and P-Selectin).  
These monocytes then start to migrate to the subendothelial space and start accumulating. 
This process is mediated by the action of protein molecules known as chemoattractant cytokines 
or chemokines like monocyte chemoattractant protein 1 (MCP-1), Interleukin-8 (CXCL8), 
Interferon-γ, etc. These monocytes take up the lipids present in the intima and become a foam 
cell or lipid-laden macrophage. These foam cells start to replicate due to the presence of 
macrophage colony-stimulating factor (M-CSF).  
The macrophage foam cells which are present in the artery wall serve not only as a 
reservoir for excess lipid but also as a source of proinflammatory mediators like cytokines and 
chemokines and various eicosanoids and lipids such as platelet-activating factor. They also serve 
as a source of large quantities of oxidant species. These processes constitute the innate immunity 
which is an amplification of inflammation without the presence of an antigen. Dendritic cells in 
atherosclerotic lesions can present antigens to the T cells. These antigens include modified 
lipoproteins, beta2-glycoprotein Ib, heat shock proteins and infectious agents.  
 
  
Figure 1: Pathogenesis of atherosclerosis 
 
 
 
Figure 2: Plaque formation 
 
 
 The next process involves the smooth muscle cells (SMCs). These smooth muscle cells 
migrate from the tunica media to the tunica intima. This process is facilitated by the presence of 
factors like platelet derived growth factor (PDGF). There is proliferation of smooth muscle cells 
in the intima. These SMCs in the atherosclerotic intima also exhibit a less mature phenotype than 
the quiescent SMCs in the normal arterial medial layer. This SMC replication causes the 
formation of a fibrous capsule covering the fatty streak. 
Extracellular matrix itself makes up much of the volume of an advanced atherosclerotic 
plaque. The majority of extracellular matrix macromolecules that accumulate in atheroma 
include interstitial collagen type I, collagen type III, proteoglycans such as versican, biglycan, 
aggrecan, decorin and elastins. These macromolecules are broken down by matrix 
metalloproteinases (MMPs). Dissolution of extracellular matrix macromolecules will lead to 
migration of SMCs as they migrate into the tunica intima from the media through a dense 
extracellular matrix and the internal elastic lamina. Overexpression of proteinase inhibitors 
(known as tissue inhibitors of metalloproteinases, or TIMPs) can delay SMC accumulation in the 
intima of a plaque 
[26]
.  
Atheroscerotic plaques develop their own microcirculation which is mediated by vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF). The abundant 
microvessels in plaques will lead to a relatively large surface area through which leukocytes will 
migrate into the plaque. Some plaques can become calcified due to deposition of calcium.  
As time goes on, enzymatic degradation can cause erosion of the fibrous cap. The 
endothelial cap separating the plaque and blood flow becomes thin and fragile. Rupture of the 
plaque may be due to the mechanical stress on the arteries or due to reduced collagen secretion 
 Figure 3:  Evolution of Atherosclerosis 
 
 by the smooth muscle cells leading to rupture of the cap. This causes spilling of highly 
atherogenic plaque contents into blood stream which triggers the formation of thrombus. 
Pathophysiology of Myocardial Infarction 
 
Plaque disruption leads to exposure of highly atherogenic plaque content to blood stream which 
leads to formation of a thrombus. Occlusion of the entire vessel will lead to ST elevation 
myocardial infarction. This transmural injury and infarction leads to change in the sequence of 
depolarization producing the characteristic ECG changes. Size of the infarct depends largely on 
the magnitude of coronary collateral flow which if present may minimize the area of infarction. 
The location of infarct depends on the vessel that is involved. 
Figure 4: Evolution of Myocardial Infarction 
 
  As time progresses, certain characteristic changes take place in the infarcted zone of the 
heart. The various gross changes and histological changes are given below 
 
Time Gross Examination Histopathology 
0 - 0.5 hours 
 
None 
 
None 
0.5 – 4 hours 
 
None 
 
Glycogen Depletion, as seen with a PAS 
Stain 
Possibly waviness of fibers at border 
4 – 12 hours Sometimes dark mottling Initiation of coagulation necrosis 
Edema 
Hemorrhage 
12 – 24 hours Dark mottling Ongoing coagulation necrosis 
Karyopyknosis 
Hypereosinophilia of myocytes 
Contraction band necrosis in margins 
Beginning of neutrophil infiltration 
1 – 3 days Infarct center becomes yellow-tan Continued coagulation necrosis 
Loss of nuclei and striations 
Increased infiltration of neutrophils to 
interstitium 
3 – 7 days Hyperemia at border 
Softening yellow-tan center 
Beginning of disintegration of dead muscle 
fibers 
Necrosis of neutrophils 
Beginning of macrophage removal of dead 
cells at border 
7 – 10 days Maximally soft and yellow-tan 
Red-tan margins 
Increased phagocytosis of dead cells at 
border 
Beginning of granulation tissue formation at 
margins 
10 – 34 days Red-gray and depressed borders Mature granulation tissue with type I 
collagen 
2 – 8 weeks Gray-white granulation tissue Increased collagen deposition 
Decreased cellularity 
 More than 2 months 
 
 
Completed scarring 
 
   Dense collagenous scar formed 
Pathophysiology of Myocardial Infarction 
LV Function 
 Interruption of antegrade flow in a coronary vessel leads to abnormal or loss of 
contractile function in the myocardium that is supplied by that vessel. Four abnormal patterns of 
contraction can develop. Dyssynchrony causes dissociation in time between the contraction in 
 the affected myocardium and surrounding myocardium. Hypokinesis is reduction in the length of 
shortening. Akinesis is cessation of shortening. Dyskinesis causes paradoxical expansion and 
bulging. There is hyperkinesis of the surrounding myocardium to maintain the cardiac output but 
it subsides within two weeks. 
 If a large portion of the left ventricular myocardium is involved, LV pump action 
becomes decreased leading to low cardiac output and stroke volume, reduced blood pressure and 
elevated end systolic volume. Initially, the LV dilates as necrotic myocytes slip past each other. 
The infarct zone thins and elongates leading to infarct expansion. Later fibrous tissue is formed 
which leads to increased stiffness of the myocardium. 
 Left ventricular function is reduced when more than 15% of the myocardium is involved. 
Clinical signs of heart failure develop at 25% and cardiogenic shock occurs at 40%. Diastolic 
dysfunction also occurs in MI as a result of decrease in the peak rate of decline in LV pressure, 
an increase in the time for the fall in LV pressure, and an initial rise in LV end-diastolic pressure. 
LV Remodeling 
 As a consequence of myocardial infarction, certain changes take place in the size, shape 
and thickness of the infarcted and the non-infarcted myocardium. These are called Ventricular 
Remodeling. Other than the size of infarct, there are two other major factors which determine the 
process of remodeling. First is the elevated ventricular pressure which leads to increased wall 
stress and infarct expansion. Other is the patency of the infarct artery which can accelerate scar 
formation and prevent remodeling. 
 Infarct expansion is defined as “acute dilation and thinning of the area of infarction not 
explained by additional myocardial necrosis.” [27]. This can be explained by mechanisms like 
 slippage of muscle bundles, disruption of normal cardiac cells and due to tissue loss within the 
infarct zone. The apex is the thinnest region and is especially prone for infarct expansion. Infarct 
expansion is associated with increased incidence of heart failure, aneurysm formation and 
increased mortality. 
 Dilatation of the non-infarcted zone of the myocardium occurs as a result of a 
compensatory mechanism to maintain the normal cardiac output. Also the increased pressure 
load on the non-infarcted myocardium leads to hypertrophy of those areas which helps maintain 
a normal cardiac output. 
 Ventricular remodeling after an acute myocardial infarction can be modified by a number 
of therapeutic interventions. Acute reperfusion restricts the area of myocardial infarction and 
prevents dilatation of the left ventricle. Treatment with angiotensin II inhibitors provides cardiac 
protection by reducing the endothelial dysfunction and reducing ventricular remodeling in 
addition to its direct antiatherogenic effects. Aldosterone inhibition also reduces collagen 
deposition and decreases the development of ventricular arrhythmias. 
Incidence of Heart Failure after Myocardial Infarction 
 There are several studies that have studied the relationship between door to balloon time 
and symptom to balloon time. Several of these studies found that prolongation in these times lead 
to a reduced index left ventricular function. These studies include the Harmonizing Outcomes 
with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial that 
included 2639 patients and found that left ventricular ejection fraction was inversely associated 
with the door to balloon time 
[29]
. 
  Ng and el 
[30]
 found that after myocardial infarction, LVEF was significantly highera 
mong patients with shorter symptom to balloon time when compared with those who had longer 
times (n=2,529, P=.029). Also a study done on 1723 Polish patients 
[31]
 showed a significant 
difference in the mean LV ejection fraction among patients with the shortest symptom to balloon 
time (<1.5hours, 48% ± 13.4%) compared to those with the longest reperfusion time (>6hours, 
31.4% ± 11.3%, P=.05). 
 Some studies such as Controlled Abciximab and Device Investigation to Lower Late 
Angioplasty Complications (CADILLAC) trial 
[32]
, Stent Primary Angioplasty in Myocardial 
Infarction (PAMI) trial 
[33]
, Enhanced Myocardial Efficacy and Removal by Aspiration of 
Liberated Debris (EMERALD) trial 
[34]
 and a few more studies found no association between 
reduced LV ejection fraction and the symptom to balloon time. The explanation offered was that 
the early reduced LV ejection fraction could possibly be due to myocardial stunning or due to 
hibernating myocardium rather than denoting the size of the infarct. This could also be explained 
by the improvement in the LV ejection fraction on follow up. 
 Most of the trials which included LV ejection fraction at follow up as a parameter 
reported a significant improvement in LVEF on follow up compared to the index LVEF in 
patients who had shorter reperfusion times. One randomized study 
[35] 
found that longer 
reperfusion time was an independent predictor of worsening of LV function in 43% of the 
subjects at 6 months (HR 1.43, 95% CI 1.06-1.94). The PAMI trial noted an improvement in 
LVEF of 12% on follow up in patients with reperfusion time of < 2 hours as compared to an 
improvement of 4% in patients with reperfusion time of > 2 hours. The final LVEF at 6 months 
depended more on vessel patency than on reperfusion time in these trials. 
 List of trials studying time to reperfusion and index LVEF 
[36]
  
 
  
  
  
 
 
 
  
 
 
 
  
  A total of 12 studies were done to establish a relationship between reperfusion time and 
index heart failure. 11 of these studies showed significant association between these 2 variables. 
The largest trial by American College of Cardiology National Cardiovascular Data Registry 
[37]
 
showed an absolute increase in heart failure by 5.3% in patients with door to balloon time of 
>120 minutes compared to a time of <60 minutes. The largest study done by Ng S et al 
[30]
 
showed that for every 1 hour increase in reperfusion time, there was an increase in incidence of 
heart failure by 4%. 
 Many trials including Danish Acute Myocardial Infarction 2 (DANAMI-2) study have 
shown that primary angioplasty has better outcome compared to intra venous thrombolysis in 
terms of 30 days mortality. Another trial done by Henriques et al 
[38]
 has established that primary 
angioplasty has better outcome in terms of LVEF in patients who have anterior wall myocardial 
infarction compared to intra venous thrombolysis. 
  
 MATERIALS AND METHODS 
Source of Data 
 This study was done in PSG Hospitals which is affiliated to PSG Institute of Medical 
Sciences and research in Coimbatore, Tamil Nadu. All patients presenting to the hospital with 
acute STEMI and undergoing thrombolysis or primary PCI were included in the study between 
the period of March to December 2013. A total of 93 patients were included out of which 32 
underwent primary PCI and 61 underwent thrombolysis with streptokinase. 40 of 61 patients 
who were thrombolysed underwent coronary angiogram for risk stratification and further 
management. 
Methodology 
 A total of 93 consecutive patients with STEMI undergoing either primary PCI or 
thrombolysis were included in the study after obtaining proper consent from the patients. Age, 
sex, time of onset of chest pain and the time of start of thrombolysis or time of balloon dilatation 
were noted. Presence or absence of diabetes mellitus, hypertension and smoking history were 
recorded. The left ventricular ejection fraction within 24 hours of admission and before discharge 
were recorded by a single operator to avoid inter observer variability using Simpson‟s Method. 
Presence of heart failure was monitored during the hospital stay based on the Framingham 
Criteria for Heart Failure. Number of vessels with 50% or more stenosis was noted either during 
primary PCI or during elective coronary angiogram. Statistical analysis was done using 
Pearson‟s correlation coefficient, Chi square test and Multivariate analysis using SPSS software. 
 Inclusion Criteria 
 All patients presenting to PSG hospitals with diagnosis of acute STEMI, who underwent 
reperfusion with either thrombolysis or primary PCI during the time period of March 
2013 and December 2013. 
Exclusion Criteria 
 Patients with previous history of coronary artery disease were excluded. 
 Patients with previous history of heart failure were excluded. 
 Patients with structural heart disease like valvular heart disease or any congenital heart 
disease were excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 Protocol of the Study 
 
 
Entry Point 
Patients presenting with acute STEMI who are undergoing revascularization 
 
History 
Time of onset of chest pain 
Past history of diabetes, hypertension, smoking 
Past history of CAD, heart failure, structural heart disease 
 
Management 
Patient undergoes either thrombolysis or primary PCI 
Time from onset of chest pain to start of thrombolysis or start of balloon dilation is noted 
 
Follow Up 
Patient followed up for signs of heart failure 
LV ejection fraction by echocardiography using Simpson‟s method is determined during the first 
24 hours and on discharge 
Number of vessels with 50% or more lesions is noted during primary PCI or elective coronary 
angiogram 
 
 
 Definitions 
 
Definition of MI 
(ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction)
[6] 
Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin(cTn)] 
with at least one value above the 99
th
 percentile upper reference limit (URL) and with at least 
one of the following: 
 Symptoms of ischemia 
 New or presumed new significant ST segment and T wave (ST–T) changes or new left 
bundle branch block(LBBB) 
 Development of pathological Q waves in the ECG 
 Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality 
 Identification of an intracoronary thrombus by angiography or autopsy 
ECG Criteria for STEMI 
 (ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction)
[6] 
 New ST segment elevation at the J point in two contiguous leads with elevation >0.1 mV 
in all leads other than leads V2-V3 
 For leads V2-V3, ST elevation should be ≥0.2 mV in men ≥40 years, ≥0.25 mV in men 
<40 years, or ≥0.15 mV in women 
 
 Diagnostic criteria for heart failure
 [7] 
 
The Framingham criteria requires the simultaneous presence of at least 2 major criteria or 1 
major criteria and two minor criteria. Minor criteria are accepted only if they cannot be attributed 
to another cause (e.g. pulmonary hypertension, nephrotic syndrome, chronic lung disease, 
cirrhosis, etc.). 
Classification of severity of LV dysfunction based on LVEF 
( From Feigenbaum‟s Echocardiography, 7th Edition) 
 
 Normal LVEF  >55% 
 Mild LVD  45 – 54% 
 Moderate LVD 30 – 44% 
 Severe LVD  <30% 
 FLOW CHART OF THE STUDY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Patient presenting with acute STEMI 
without any exclusion criteria and planned 
for reperfusion 
Time of onset of symptoms noted 
Presence of DM, HTN, smoking noted 
Undergoing Thrombolysis Undergoing PCI 
Door to needle time noted Door to balloon time noted 
EF and signs of HF noted within 24 hours of 
admission 
Followed up for signs of HF 
Coronary lesions noted during PPCI/elective 
CAG 
EF noted before discharge 
 RESULTS 
Total of 93 patients were included in the study of which 32 underwent primary PCI and 
61 underwent thrombolysis with streptokinase. 
Table 1: General Characteristics of the study group 
Average Age 55 
Male / Female 81(87%) / 10 (13%) 
Diabetes 42 (45.16%) 
AW MI 52 (55.91%) 
Time to reperfusion  
 
0 – 3 hours 20 (21.5%) 
3 – 6 hours 44 (47.31%) 
6 – 12 hours 25 (26.88%) 
> 12 hours 4 (4.3%) 
PCI / Lysis 32 (34.4%) / 61 (65.6%) 
Deaths 5 (5.38%) 
EF > 55% 
48 
EF 45 – 54% 19 
 
EF < 45% 
26 
 
 
 
 
 Figure 5: Graphic representation of LVEF in study group 
 
 
 
 
Table 2: Characteristics based on time to reperfusion 
Time to reperfusion <3 hours 3 to 6 6 to 12 > 12 p value 
Mean Age 53.7±12.135 52.72±12.79 58.6±8.61 64±10.39 0.087 
Male 19(95.0) 35(79.54) 23(92.0) 4(100.0) 0.215 
Diabetes 11(55.0) 16(36.36) 12(48.0) 3(75.0) 0.299 
Anterior MI 6(30.0) 29(65.9) 15(60.0) 2(50.0) 0.059 
Heart failure symptoms 3(15.0) 10(22.72) 4(16.0) 3(75.0) 0.050 
Normal LV function 14(70.0) 26(59.09) 8(32.0) 0(0.0) 0.008 
LVEF < 45% 4(20.0) 7(15.9) 11(44.0) 4(100.0) 0.001 
Death 1(5) 1(2.27) 2(8.0) 1(25.0) 0.24 
 
Significant association was noted between time to reperfusion and patients developing 
signs of heart failure, patients with normal LVEF and patients with LVEF < 45%. 
 
 
 Graphic representation of LVEF based on time to reperfusion 
 
 
  
 
 
 
 
 
 
These graphs show that as time to reperfusion gets longer, less number of patients retain a 
normal left ventricular function and more patients start developing moderate and severe left 
ventricular systolic dysfunction. 
 
 
Figure 6: LVEF in patients with 
reperfusion time < 3 hours 
Figure 7: LVEF in patients with 
reperfusion time 3-6 hours 
Figure 8: LVEF in patients with 
reperfusion time 6-12 hours 
Figure 9: LVEF in patients with 
reperfusion time > 12 hours 
 Table 3: Characteristics based on PCI or thrombolysis 
 
Variables PCI Thrombolysis p value 
 
   
Total Number 32 61 
 
Mean age 54.59±12.06 55.21±11.78 0.812 
Male 29(90.62) 52(85.24)  
Diabetes 12(37.5) 30(49.2) 0.196 
Anterior wall MI 20(62.5) 32(52.5) 0.24 
Deaths 3(9.4) 2(3.3) 0.221 
 
   
< 3hours  
 
 LVEF > 55% 3(75.0) 11(68.75) 0.657 
LVEF < 45% 1(25.0) 3(18.75) 0.624 
3-6 hours  
 
 LVEF > 55% 14(82.35) 12(44.44) 0.013 
LVEF < 45% 0(0.0) 7(25.92) 0.023 
6-12 hours  
 
 LVEF > 55% 1(12.5) 7(41.17) 0.166 
LVEF < 45% 4(50.0) 7(41.17) 0.504 
>12 hours  
 
 LVEF > 55% 0(0.0) 0(0.0) - 
LVEF < 45% 3(100.0) 1(100.0) - 
 
This table shows that there are no significant differences between the general 
characteristics of the patients undergoing either thrombolysis or PCI. 
Significant differences are noted between PCI group and thrombolysis group only in the 
group of patients who undergo reperfusion between 3 and 6 hours. In this group, patients who 
undergo PCI have a significantly better LVEF than those who undergo thrombolysis. Patients 
who undergo reperfusion after 12 hours, irrespective of undergoing PCI or thrombolysis, have an 
LVEF of < 45%. 
 Figure 10: Normal LVEF based on time to reperfusion in PCI and thrombolysis groups 
 
 
Figure 11: LVEF < 45% based on time to reperfusion in PCI and thrombolysis groups 
 
 
 
 Table 4: Characteristics based on age 
Age < 30 30-40 40-50 50-60 60-70 >70 p value 
        
N value 3 8 20 30 24 8 
 
Diabetes 1(33.33) 2(25.0) 10(50.0) 13(43.33) 10(41.67) 6(75.0) 0.453 
AW MI 2(66.67) 5(62.5) 11(55.0) 15(50.0) 13(54.17) 6(75.0) 0.859 
Death 0(0.0) 0(0.0) 1(5.0) 2(6.67) 1(4.17) 1(12.5) 0.902 
< 3 hours 
 
 
LVEF > 55% 0(0.0) 1(100.0) 4(57.14) 7(100.0) 1(50.0) 1(50.0) 0.215 
LVEF < 45% 1(100.0) 0(0.0) 1(14.28) 0(0.0) 1(50.0) 1(50.0) 0.136 
3 - 6 hours 
 
 
LVEF > 55% 2(100.0) 4(66.67) 8(72.72) 6(60.0) 6(46.15) 0(0.0) 0.29 
LVEF < 45% 0(0.0) 1(16.67) 0(0.0) 3(30.0) 2(15.38) 1(50.0) 0.338 
6 – 12 hours 
 
 
LVEF > 55% 0(0.0) 0(0.0) 1(50.0) 2(18.18) 4(44.44) 0(0.0) 0.29 
LVEF < 45% 0(0.0) 0(0.0) 1(50.0) 4(36.37) 4(44.44) 2(100.0) 0.46 
>12 hours 
 
 
LVEF > 55% 0(0.0) 0(0.0) 0(0.0) 2(100.0) 0(0.0) 2(100.0) - 
LVEF < 45% 0(0.0) 0(0.0) 0(0.0) 2(100.0) 0(0.0) 2(100.0) - 
 
 From this table, age has no significant effect on the left ventricular ejection fraction and 
the development of left ventricular systolic dysfunction based on time to reperfusion. 
 
 Table 5: Characteristics based on anterior wall or non-anterior wall MI 
Variables AW MI Non AW MI p value 
 
   
N value 52 41 
 
Mean Age 54.67±12.28 55.41±10.55 0.766 
Diabetes 26(50.0) 16(39.0) 0.199 
Death 3(5.8) 2(4.9) 0.612 
 
   
< 3 hours 
 
 LVEF > 55% 4(66.67) 10(71.42) 0.613 
LVEF < 45% 2(33.33) 2(14.28) 0.343 
3-6 hours 
 
 LVEF > 55% 12(41.37) 14(93.33) 0.001 
LVEF < 45% 7(24.13) 0(0.0) 0.041 
6-12 hours 
 
 LVEF > 55% 3(20.0) 5(50.0) 0.128 
LVEF < 45% 9(60.0) 2(20.0) 0.058 
>12 hours 
 
 LVEF > 55% 0(0.0) 0(0.0) - 
LVEF < 45% 2(100.0) 2(100.0) - 
 
 Patients with anterior wall myocardial infarction have a more reduced left ventricular 
ejection fraction than those with non-anterior wall myocardial infarctions. There is significant 
difference between anterior and non-anterior wall myocardial infarction in the group with a 
reperfusion time of 3 to 6 hours. After 6 hours, the rate of reduction in LVEF increases in the 
non-anterior wall myocardial infarction. Therefore, patients with AWMI develop reduced LVEF 
faster than patients with non-AWMI. 
 
  
Table 6: Characteristics based on presence of diabetes mellitus 
 Diabetics Non Diabetics P Value 
N value 42 51 
 
Mean Age 56.45±11.96 53.80±11.46 0.521 
AW MI 26(61.94) 26(50.9) 0.199 
Death 4(9.5) 1(1.96) 0.126 
< 3 hours 
 
 
LVEF > 55% 7(63.63) 7(77.77) 0.426 
 
LVEF < 45% 3(27.27) 1(11.11) 0.375 
3 - 6 hours 
 
 
LVEF > 55% 8(50.0) 18(64.28) 0.271 
LVEF < 45% 4(25.0) 3(10.71) 0.205 
6 – 12 hours 
 
 
LVEF > 55% 5(41.67) 3(23.07) 0.286 
LVEF < 45% 7(58.33) 4(30.7) 0.163 
>12 hours 
 
 
LVEF > 55% 0(0.0) 0(0.0) - 
LVEF < 45% 3(100.0) 1(100.0) - 
 
 There was no significant relationship between the presence or absence of diabetes 
mellitus and left ventricular ejection fraction after ST elevation myocardial infarction based on 
time to reperfusion. 
 
 
 
  
 
Table 7: Characteristics based on number of vessels involved 
 1 vessel 2 vessel 3 vessel p value 
N Value 34 16 20 
 
Mean age 51.44±11.33 55.60±9.78 59.95±11.37 0.079 
Diabetes 10(29.41) 11(68.75) 8(40.0) 0.038 
AW MI 23(67.64) 9(56.25) 45(20.0) 0.324 
Death 2(5.9) 1(6.2) 1(5.0) 0.992 
< 3 hours 
 
 LVEF > 55% 1(50.0) 5(62.5) 4(100.0) 0.505 
LVEF < 45% 1(50.0) 1(12.5) 0(0.0) 0.381 
3 - 6  hours 
 
 LVEF > 55% 11(61.11) 1(25.0) 8(80.0) 0.243 
LVEF < 45% 2(11.11) 1(25.0) 0(0.0) 0.16 
6 – 12 hours 
 
 LVEF > 55% 3(23.07) 1(33.33) 3(75.0) 0.24 
LVEF < 45% 5(38.46) 2(66.67) 1(25.0) 0.595 
>12 hours 
 
 LVEF > 55% 0(0.0) 0(0.0) 0(0.0) - 
LVEF < 45% 1(100.0) 1(100.0) 2(100.0) - 
 
 This study also showed no significant relationship between left ventricular ejection 
fraction after myocardial infarction and the number of vessels involved with more than 50% 
stenosis in coronary angiogram based on time to reperfusion. 
 
  
Table 8: Multiple Regression Analysis 
   
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
R
2
 Overall  
p-value 
B Std. Error Beta 
 (Constant) .882 .330  2.676 .009   
 Age .003 .003 .088 .903 .369   
 Gender -.048 .122 -.039 -.394 .694   
 Time period .000 .012 -.005 -.046 .964   
 DM .073 .077 .089 .946 .347   
 SHT .047 .079 .055 .587 .559 0.313 0.000 
 Smoking -.073 .084 -.088 -.872 .386   
 
No. of 
vessels 
.023 .036 .061 .651 .517   
 LVEF -.017 .004 -.468 -4.494 .000   
a. Predictors: (Constant), EF, SHT, vessels, Gender, DM, Age, Time period, Smoking 
b. Dependent Variable: HF 
       
 This table shows that though all the factors together contribute to heart failure by 31.3%, 
LVEF has the strongest association.  
 DISCUSSION 
 A total of 93 patients were included in this study. All patients presented to the emergency 
department with acute onset of chest pain and were diagnosed as ST elevation myocardial 
infarction. Out of 93, 32 patients underwent primary angioplasty and 61 underwent intra venous 
thrombolysis with streptokinase. All patients were given the option of both thrombolysis and 
primary PCI. The decision to do thrombolysis or primary PCI was made by the patients and 
family considering the costs involved. 
Age and sex distribution 
 In this study, the mean age was 57.25. Subjects below 40 years of age constituted 11.8% 
(N=11) and subjects over 70 years of age constituted 8.6% (N=8). The youngest age encountered 
was 27 and the oldest age was 77. Males constituted 89.25% (N=83) and females 10.75% 
(N=10) which again shows that males are more prone to coronary artery disease than females. 
The sex ratio in this trial was 8.3:1. The lowest age among females was 47 which again shows 
that coronary artery disease occurs later in age among females. 
Time to reperfusion 
 The reperfusion time depends on two factors. The initial period is the symptom onset to 
presentation time which depends on the patient and his awareness of symptoms of coronary 
artery disease and the availability of quick transportation to reach the hospital. The later part is 
the door to needle time which depends on the availability of trained staff and a fully operational 
cardiac cauterization lab and an intensive cardiac care unit. 
  Various studies have shown that the shorter the reperfusion time, the better is the left 
ventricular function and lower the mortality.  The Fibrinolytic Therapy Trialists Collaborative 
Group did a meta-analysis on 9 randomized trials which included over 58,000 patients and found 
a significant relationship between mortality benefit and time to reperfusion up to 12 hours. The 
Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary 
Arteries (GUSTO) Trial has shown that there is mortality benefit up to a period of 12 hours with 
thrombolysis (5.3% at 2h, 5.9% at 2 to 4h, 8.5% at 4 to 6h and 8.9% at 6h). 
The average time to reperfusion, which is the time from the onset of chest pain to start of 
thrombolysis or balloon dilatation was 5 hours and 30 minutes. Similar to GUSTO and other 
trials, this study has shown that maximum benefit occurred up to 6 hours after which some 
benefit was noted up to 12 hours but all patients who had a reperfusion time of more than 12 
hours had an LVEF of < 45%. 
Most of the patients in this study had a reperfusion time of 3 to 12 hours (N=69, 74.19%). 
This study shows that time to reperfusion has a significant association with LVEF. As time to 
reperfusion increases, the LVEF is significantly reduced. LVEF was < 45% in 17.18% of 
patients who had a reperfusion time of less than 6 hours (N=11, p = .001), 44% of patients with 
reperfusion time between 6 and 12 (N=11) and 100% of patients with reperfusion time of more 
than 12 hours (N=4). 
Difference between PCI and Thrombolysis 
 Of the 93 patients in this study, 32 underwent primary PCI and 61 underwent 
thrombolysis. In patients with reperfusion time of less than 3 hours, 75% in PCI group had 
normal LVEF compared to 68.75% in thrombolysis group with no statistical significance (p = 
 0.657). In reperfusion time of 3 to 6 hours, 82.35% in PCI group had normal LVEF compared to 
44.4% in thrombolysis group showing statistically significant difference (p=0.013).  
When reperfusion time was 6 to 12 and more than 12 hours, 12.5% and 0% in PCI group 
and 41.17% and 0% in thrombolysis group respectively had normal LVEF with no statistical 
significance between the groups (p=0.166). This shows that maximum benefit of primary PCI 
over thrombolysis is obtained in those who have a reperfusion time of 3 to 6 hours. Similar 
results were obtained in the study done by Brodie et al which showed no significant difference 
between PCI and thrombolysis groups up to 6 hours but showed better outcome in PCI group 
from 6 to 12 hours. This was attributed to limitation of thrombolysis to first 6 hours previously 
when the trial was done. 
The reason for presence of reduced LVEF as time to reperfusion increases may be due to 
the larger area of myocardium that is involved as the time of vessel non patency increases and 
also because of the fact that infarction zone expands as the previously stunned myocardium also 
begins to undergo necrosis as the duration of ischemia increases. 
Difference between AW STEMI and non-AW STEMI 
 52 of the 93 patients who presented with STEMI had AW STEMI while the remaining 41 
patients had lateral wall, inferior wall or posterior wall STEMI. When reperfusion time was less 
than 3 hours, 66.67% of AW STEMI patients and 71.42% of non-AW STEMI patients had 
normal LVEF showing no statistical significance (p=0.613). In those with reperfusion time of 3 
to 6 hours, only 41.37% of patients with AW STEMI had normal LVEF compared to 93.3% of 
patients in non-AW STEMI group who had normal LVEF and was statistically significant 
(p=0.001). 
  When the reperfusion time was 6 to 12 hours, only 20% of AW STEMI and 50% of non-
AW STEMI had normal LVEF and there was no statistical difference (p=0.128). None of the 
patients who presented after 12 hours in both groups had normal LVEF. This shows that AW 
STEMI patients develop reduced LVEF faster than non-AW STEMI patients and this difference 
is observed up to 6 hours. After 6 hours, non-AW STEMI patients also start developing reduced 
LVEF and as time progresses, have no statistical difference from those who have AW STEMI. 
The reason for higher incidence of reduced LVEF in AW STEMI may be due to the fact that AW 
STEMI puts a larger area of myocardium at risk. 
Effect of Age on LVEF 
 53.76% of the patients in this study (N=50) were in the age group of 40 to 60 years. 
Subjects below 40 years of age constituted 11.8% (N=11) and subjects over 60 years of age 
constituted 34.4% (N=32). There was no statistical difference between various age groups and 
the development of LVEF. However, it was noted that older individuals had longer reperfusion 
times. All 4 of the patients who were above 70 years of age had a reperfusion time of over 12 
hours. The reasons for this delay need to be evaluated. 
Role of Diabetes in LVEF 
 Of the 93 patients enrolled in this study, 42 patients (45.16%) had diabetes mellitus 
which is higher than the 30% described in other trials. Statistical analysis of the data showed that 
there was no significant association between the presence of diabetes mellitus and the presence 
of normal LVEF or development of reduced LVEF. A study done by Alegria et al 
[39] 
showed 
that patients with diabetes only had a modestly increased size of the infarct and reduced LVEF 
 than non-diabetics. Diabetics are known to do poorly even after reperfusion with higher mortality 
compared to non-diabetics. The increased mortality among diabetics could not be explained by 
these moderate changes after MI in diabetics. 
Symptomatic Heart Failure 
 Though 45 of the 93 patients (48.38%) had reduction in LVEF, only 20 of the 93 patients 
(21.5%) developed signs of heart failure based on the Framingham‟s criteria. To find out the 
reasons for development of signs and symptoms of heart failure in some but not all patients with 
reduced LVEF, a multiple regression analysis of the data was done.  
Multiple regression analysis showed that factors such as age, sex, diabetes, hypertension, 
smoking, reperfusion time, number of vessels involved and LVEF were all together contributing 
to the development of signs and symptoms of heart failure. Among these, LVEF had the 
strongest correlation with the development of symptoms of heart failure. Some studies
[40]
 have 
shown that time to reperfusion does not correlate strongly with development of heart failure 
since a significant part of the myocardium may only be stunned and not necrosed during the 
initial few hours. 
 
 
 
 
 
 LIMITATIONS 
 
 Number of subjects enrolled in the study was small. Larger number may have shown 
statistical significance among the variables. 
 The study did not include follow up left ventricular ejection fraction assessment even 
though it has been shown that LVEF improves at 6 months. 
 Left ventricular ejection fraction assessment by echocardiography, though assessed by a 
single observer to avoid bias, is still not a very accurate method. 
 Exact time of onset of chest pain is difficult to obtain from history. Incorrect data can 
lead to errors in statistical analysis of variables.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
 
1. LVEF strongly depends on the reperfusion time. Longer reperfusion times lead to a 
significant reduction in LVEF 
2. Primary PCI is superior to thrombolysis with streptokinase in terms of retaining a normal 
LVEF. This is very significant in those undergoing reperfusion between 3 and 6 hours of 
symptom onset. 
3. Patients with reperfusion times of over 12 hours, irrespective of mode of 
revascularization or any other variables, have a significant reduction in LVEF. 
4. AW STEMI patients tend to have higher incidence of reduced LVEF compared to non-
AW STEMI. The percentage of patients with AWMI who had reduced LVEF was 
significantly higher than non AW STEMI group when time to reperfusion was between 3 
and 6 hours. 
5. Non-AW STEMI had better maintained LVEF compared to AW STEMI patients but this 
difference becomes insignificant when time to reperfusion exceeds 6 hours. 
6. Even though older patients showed higher incidence of reduced LVEF, this was not 
significant. 
7. Reason for longer reperfusion times in older individuals needs to be studied. 
8. Presence or absence of diabetes had no significant relationship to the development of 
reduced LVEF after acute STEMI. 
9. The number of vessels with more than 50% stenosis as seen during angiogram had no 
association to the development of reduced LVEF after acute STEMI. 
 10. Not all patients with moderate to severe reduction in LVEF developed signs of heart 
failure. Multiple regression analysis showed that there was significant association 
between developing signs of heart failure and other variables like age, sex, diabetes, 
hypertension, smoking, family history and number of vessels involved with the most 
significant variable being LVEF.  
11. This study stresses the need for creating patient awareness about coronary heart disease 
to reduce symptom to door time and the need for hospitals with PCI facilities and a well-
organized staff to reduce the door to balloon time thereby reducing the overall symptom 
to balloon time and preventing the development of reduced LVEF which is the most 
common cause of morbidity and mortality after an acute myocardial infarction. 
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 ANNEXURE I 
List of Abbreviations Used 
 
CAD : Coronary Artery Disease 
DM : Diabetes Mellitus 
SHT : Hypertension 
CVD 
ACS 
MI 
PCI 
ECG 
SMC 
CHD 
STEMI 
IHD 
AW 
LVEF 
LVD 
DALY 
: Cardio Vascular Disease 
: Acute Coronary Syndrome 
: Myocardial infarction 
: Percutaneous coronary intervention 
: Electro cardiogram 
: Smooth muscle cell 
: Coronary heart disease 
: ST elevation myocardial infarction 
: Ischemic heart disease 
: Anterior wall 
: Left ventricular ejection fraction 
: Left ventricular dysfunction 
: Disability Adjusted Life Years 
  
 
 ANNEXURE II 
Case Proforma 
 
Name:                                                    Age:                      Sex: 
IP No:                                                   OP No: 
Diagnosis:   AW  /  LW  /  IW  /  PW  /  RV    STEMI                  Killip Class:  I  / II  /  III  /  IV 
Risk Factors:  DM  /  SHT  /  Smoker  /  Family History 
Plan:  PCI  /  Thrombolysis 
Onset of Chest pain                                            : 
Time of presentation to EMD                            : 
Time of start of thrombolysis/Balloon dilation : 
Total symptom to needle/balloon time              : 
 
Presence of signs of HF during hospital stay:  Yes  /  No 
Use of diuretics during hospital stay             :  Yes  /  No 
 
LVEF 
 Day 1:    Day 5: 
Vessels with >50% lesion: LAD LCX RCA RI 
Complications: 
 
Death:   Yes  /  No 
 
 
 Master Chart: 
S. 
No 
Ag
e 
Se
x 
    M
I 
    Lysi
s 
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et to 
N/B 
Killi
p 
H
F 
Diu 
Reti
c 
E
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E
F  
D
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SH
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F
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Vessels 
  
Deat
h 
      A
W 
L
W 
I
W 
P
W 
R
V 
        D
1 
D
5 
       LA
D 
LC
X 
RC
A 
  
1 31 1 1 0 0 0 0 1 3.15 1 0 1 40 36 1 1 1 1 1 0 0 0 
2 59 1 1 0 0 0 0 1 8.15 1 0 2 40 40 1 1 1 0 1 0 1 0 
3 70 1 1 0 1 0 0 0 3.5 1 0 0 35 52 0 0 0 0 1 0 0 0 
4 34 1 1 0 0 0 0 0 5 1 0 0 55 60 1 0 0 0 1 1 0 0 
5 53 1 1 1 0 0 0 1 4 3 1 1 30 38 1 0 1 0 1 0 1 0 
6 51 1 0 0 1 1 0 0 12 1 0 0 45 47 0 1 1 0 0 1 0 0 
7 40 1 0 1 1 0 0 1 6.45 1 0 0 76 72 0 1 1 0 0 1 0 0 
8 41 1 1 0 0 0 0 0 5.4 1 0 0 60 58 0 0 1 1 1 0 0 0 
9 44 1 1 0 0 0 0 1 2.3 2 1 1 35 56 1 1 0 1 1 1 1 0 
10 49 1 0 0 1 0 0 0 5.15 1 0 0 56 61 1 0 1 0 0 0 1 0 
11 55 1 0 1 0 0 0 0 21.5 2 1 1 20 X 1 0 0 0 RI 1 1 1 
12 65 1 0 1 1 1 1 1 3.4 1 0 0 40 51 0 1 1 0 1 1 1 0 
13 57 1 0 0 1 0 0 1 8.4 1 0 0 60 61 1 0 1 0 0 0 1 0 
14 29 1 1 0 0 0 0 0 5 1 0 0 60 68 0 0 1 1 1 0 0 0 
15 37 1 1 0 0 0 0 0 3.1 1 0 0 66 68 0 1 1 0 1 0 0 0 
16 62 1 0 1 1 1 0 1 8 1 0 0 45 47 0 1 0 0 0 0 1 0 
17 60 1 0 0 1 1 1 1 3 1 0 0 60 68 0 0 0 0 x x x 0 
18 65 1 0 0 1 0 0 1 7.4 1 0 0 50 43 1 0 0 0 x x x 0 
19 51 1 1 0 0 0 0 1 7.1 1 0 0 45 50 0 0 0 0 1 0 0 0 
20 64 1 1 0 0 0 0 1 9.5 1 0 0 60 58 1 0 0 0 1 1 1 0 
21 53 1 1 0 0 0 0 0 5.5 1 0 0 60 68 0 0 0 0 1 1 1 0 
22 38 1 1 1 0 0 0 1 3.5 1 0 0 45 47 0 0 0 1 1 0 0 0 
23 60 1 0 0 1 1 0 1 8.1 1 0 0 50 52 0 0 1 0 x x x 0 
 24 52 1 1 0 0 0 0 0 8.18 1 0 0 45 51 0 0 1 0 1 0 0 0 
25 65 1 1 0 0 0 0 0 3.06 1 0 0 60 56 0 0 0 0 1 1 1 0 
26 65 1 0 1 1 1 0 1 3.4 1 0 0 55 55 1 1 0 0 x x x 0 
27 59 1 1 0 0 0 0 1 4.1 1 1 1 40 42 0 0 1 0 x x x 0 
28 55 0 1 0 0 0 0 0 11.3 1 0 0 30 28 1 1 0 0 1 0 0 0 
29 60 1 0 0 1 0 0 1 1 1 0 0 60 57 0 1 0 0 1 0 1 0 
30 37 1 0 0 1 1 1 1 1.4 1 0 0 50 58 0 0 0 0 1 1 1 0 
31 61 0 1 0 0 0 0 1 5.1 1 0 0 50 52 0 0 0 0 1 0 1 0 
32 54 1 1 0 0 0 0 0 3.5 1 0 0 55 48 0 0 0 0 1 0 0 0 
33 62 1 0 1 0 0 0 1 2.35 1 0 0 40 34 0 1 0 0 0 1 1 0 
34 65 0 0 0 1 1 1 1 4.2 1 0 0 60 67 0 0 0 0 x x x 0 
35 30 1 0 1 1 0 0 1 6 1 0 0 60 58 0 0 0 0 0 0 0 0 
36 59 1 0 1 1 1 1 1 3 1 0 0 60 64 1 1 1 0 x x x 0 
37 47 1 1 0 0 0 0 0 11.5 1 0 0 20 X 0 0 0 0 1 0 0 1 
38 56 1 0 0 1 1 1 0 3 1 0 0 58 65 0 0 1 0 0 1 1 0 
39 67 1 0 0 1 1 1 1 11.2 1 0 0 60 67 1 1 0 0 0 1 1 0 
40 63 0 0 0 1 1 1 1 5.1 2 1 1 56 59 1 1 0 0 1 1 1 0 
41 52 1 0 0 1 0 1 1 6.2 2 1 1 55 41 0 0 1 0 x x x 0 
42 52 1 1 0 0 0 0 1 2.43 1 0 0 60 66 1 1 0 1 1 1 0 0 
43 46 1 0 0 1 1 0 1 2 1 0 0 49 51 1 0 1 0 0 1 1 0 
44 43 1 0 1 1 1 1 0 3.1 1 0 0 60 58 0 0 1 0 1 1 1 0 
45 73 1 1 0 0 0 0 1 13.4 3 1 1 35 43 1 1 0 0 1 1 0 0 
46 49 1 0 1 1 1 0 0 3.25 1 0 0 60 58 1 0 1 0 0 1 0 0 
47 47 1 1 0 0 0 0 1 4 1 0 0 60 65 0 1 1 0 x x x 0 
48 42 0 0 0 1 1 1 1 5.1 1 0 0 60 63 0 1 0 0 0 0 1 0 
49 72 1 1 1 0 0 0 1 5.2 1 0 0 55 46 1 1 1 0 1 1 1 0 
50 75 1 1 1 0 0 0 1 9.25 1 0 1 45 38 1 0 1 0 x x x 0 
51 57 1 0 0 1 1 1 1 7.45 1 0 0 60 64 0 1 1 0 1 1 1 0 
52 41 1 1 0 0 0 0 1 6 2 1 1 45 48 0 1 0 0 1 0 0 0 
53 35 1 1 0 0 0 0 0 4.56 1 0 0 60 57 0 0 0 1 1 0 0 0 
 54 69 0 1 0 0 0 0 1 5.35 1 0 0 55 47 0 1 0 0 x x x 0 
55 55 1 1 0 0 0 0 0 3.4 1 0 0 60 59 0 1 1 0 1 0 0 0 
56 58 1 0 0 1 1 0 0 6 2 1 1 55 56 0 0 0 1 1 1 1 0 
57 47 0 1 0 0 0 0 1 3.05 1 0 0 65 73 0 0 0 0 1 0 0 0 
58 50 1 1 1 1 0 0 1 3 2 1 1 30 33 1 0 0 0 x x x 0 
59 77 1 0 1 0 1 0 0 2.2 1 0 0 60 58 0 1 0 0 1 1 1 0 
60 50 1 0 0 1 1 1 1 3 1 0 0 41 47 0 1 1 0 RI 1 0 0 
61 53 1 1 0 0 0 0 1 3.5 1 0 0 60 58 1 0 0 1 1 0 0 0 
62 65 1 1 0 0 0 0 1 10 1 0 0 55 56 0 0 0 1 1 0 0 0 
63 35 1 0 0 1 1 1 1 4.2 1 0 0 60 64 0 0 1 0 x x x 0 
64 65 1 1 1 0 0 0 1 6.2 1 0 2 40 42 0 0 1 0 1 0 0 0 
65 42 1 1 0 0 0 0 1 2.5 1 0 0 55 56 1 0 1 0 RI 1 0 0 
66 62 1 0 0 1 1 1 0 4.15 1 0 0 60 56 1 0 1 1 0 0 1 0 
67 44 1 1 0 0 0 0 1 5.1 1 0 0 50 48 1 0 0 0 1 0 0 0 
68 73 1 1 0 0 0 0 0 15.3 2 1 1 30 38 1 1 0 0 1 1 1 0 
69 75 1 1 1 0 0 0 0 8.5 1 1 1 45 44 1 1 0 0 1 1 1 0 
70 68 1 0 0 1 1 1 1 3.3 1 0 0 50 58 0 0 1 0 1 1 1 0 
71 75 1 0 0 1 1 0 0 2.5 4 1 1 25 X 1 1 0 0 0 1 0 1 
72 63 1 1 0 0 0 0 1 10.4 2 1 1 25 X 1 0 0 0 1 0 1 1 
73 70 1 1 0 0 0 0 1 4.2 2 1 1 50 48 1 1 0 0 x x x 0 
74 55 1 0 0 1 1 0 0 12.6 1 0 0 40 42 0 1 0 1 0 0 1 0 
75 63 0 1 0 0 0 0 0 6.1 1 0 0 55 62 1 0 0 0 1 1 1 0 
76 56 1 1 0 0 0 0 0 5.58 1 0 0 60 63 0 0 1 0 1 1 1 0 
77 27 1 1 0 0 0 0 1 2.2 1 0 0 40 44 1 0 1 0 x x x 0 
78 43 1 0 1 0 0 0 1 6.55 1 0 0 50 55 1 0 1 0 0 0 0 0 
79 60 0 0 0 1 1 0 1 2.4 1 0 0 55 57 1 0 0 0 x x x 0 
80 68 1 1 0 0 0 0 1 4 1 0 0 35 35 1 0 0 0 x x x 0 
81 63 1 1 0 0 0 0 0 9.45 3 1 1 45 44 0 0 1 0 1 0 0 0 
82 70 1 1 0 0 0 0 1 5.3 2 1 1 30 35 0 0 0 0 1 0 0 0 
83 57 1 1 0 0 0 0 1 9.3 1 0 2 45 42 1 0 0 0 1 0 0 0 
 84 57 1 1 0 0 0 0 0 6.3 1 0 0 50 45 0 0 0 0 1 0 0 0 
85 48 0 1 0 0 0 0 0 3.38 2 1 1 50 46 1 1 0 0 1 0 1 0 
86 55 0 1 1 0 0 0 1 6 3 1 1 40 X 1 0 0 0 x x x 1 
87 55 1 0 0 1 1 1 0 1.5 1 0 0 60 63 1 0 1 0 0 1 1 0 
88 50 1 0 1 1 0 0 1 2.5 1 0 0 60 65 0 1 0 0 0 1 0 0 
89 56 0 0 0 1 1 0 1 4.3 1 0 0 60 59 1 1 0 0 x x x 0 
90 44 1 0 0 1 1 0 1 3.3 1 0 0 50 57 0 0 1 0 1 1 1 0 
91 71 1 1 0 0 0 0 1 3.5 2 1 1 30 36 0 0 0 0 x x x 0 
92 67 1 0 0 1 1 1 1 1.25 1 0 0 60 66 0 0 1 0 1 1 1 0 
93 45 1 1 0 0 0 0 1 2.4 1 0 0 52 58 1 0 1 0 x x x 0 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
